{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:04:25Z","timestamp":1782979465780,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.clinthera.2009.07.026","type":"journal-article","created":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T04:47:47Z","timestamp":1254804467000},"page":"1776-1786","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: A randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers"],"prefix":"10.1016","volume":"31","author":[{"given":"Ritu","family":"Lal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthamas","family":"Sukbuntherng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Cundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.07.026_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00002826-199512000-00001","article-title":"Gabapentin: Pharmacokinetics, efficacy, and safety","volume":"18","author":"Beydoun","year":"1995","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.clinthera.2009.07.026_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","article-title":"Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study","volume":"94","author":"Rice","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2009.07.026_bib3","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.clinthera.2009.07.026_bib4","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0140-6736(90)91123-R","article-title":"Gabapentin in partial epilepsy","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.07.026_bib5","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1212\/WNL.43.11.2292","article-title":"Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.07.026_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1528-1157.1994.tb02513.x","article-title":"Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled study","volume":"35","author":"Anhut","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2009.07.026_bib7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1528-1157.1999.tb00833.x","article-title":"Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicentre, double-blind, placebo-controlled study","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2009.07.026_bib8_1","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1111\/j.1528-1157.1999.tb00932.x","article-title":"Gabapentin in the management of convulsive disorders","volume":"40","author":"McLean","year":"1999","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2009.07.026_bib8_2","first-page":"S73","article-title":"Gabapentin in the management of convulsive disorders","volume":"40","author":"McLean","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2009.07.026_bib9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1528-1157.1997.tb01223.x","article-title":"Failure of absorption of gabapentin after rectal administration","volume":"38","author":"Kriel","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2009.07.026_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1157.1997.tb01078.x","article-title":"Colonic absorption of antiepileptic agents","volume":"38","author":"Stevenson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2009.07.026_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":"A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res."},{"key":"10.1016\/j.clinthera.2009.07.026_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","article-title":"Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy","volume":"31","author":"Gidal","year":"1998","journal-title":"Epilepsy Res."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.07.026_bib13","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1528-1157.1995.tb06001.x","article-title":"Gabapentin","volume":"36","author":"McLean","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2009.07.026_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.clinthera.2009.07.026_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 [(+\/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabap-entin in rats and monkeys","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2009.07.026_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported pro-drug of gabapentin","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.07.026_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 ([(alpha-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2009.07.026_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"Randomized, double-blind, placebo-controlled study of XP13512\/GSK1838262 in patients with RLS","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2009.07.026_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1016\/j.clinthera.2009.07.026_bib21","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.clinthera.2009.07.026_bib22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809002604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809002604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T00:54:00Z","timestamp":1544921640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809002604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0149291809002604"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.07.026","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}